News

Article

Long-Term ADT Plus High-Dose Radiation Provides Survival Advantage in High-Risk Prostate Cancer

Author(s):

Long-term androgen deprivation therapy plus radiation therapy led to survival benefits without increased toxicity in high-risk prostate cancer.

Long-Term ADT Plus High-Dose Radiation in Prostate Cancer | Image Credit: © Giovanni Cancemi - stock.adobe.com

Long-Term ADT Plus High-Dose Radiation

in Prostate Cancer | Image Credit:

© Giovanni Cancemi - stock.adobe.com

The use of long-term androgen deprivation therapy (ADT) plus 80 Gy of radiation therapy led to progression-free survival (PFS), cancer-specific survival, and overall survival (OS) benefits without increased toxicity vs long-term ADT plus 70 Gy of radiation therapy in patients with high-risk prostate cancer, according to long-term findings from the phase 3 GETUG-AFU 18 trial (NCT00967863) that were presented during the 2024 ASCO Genitourinary Cancers Symposium.

“Even if we use a long-term ADT, high-dose radiotherapy [80 Gy] improves PFS, cancer-specific survival, and OS, compared to a [standard dose of] 70 Gy, in [patients with] high-risk prostate cancer without increasing toxicity,” Christophe Hennequin, MD, PhD, Department of Radiation Oncology, Saint-Louis Hospital, Paris, said during a presentation of the data.

After a median follow-up of 114.2 months (95% CI, 112.5-116.5), the 5-year biochemical or clinical PFS rates in the 80 Gy (dose escalation) and 70 Gy (control) groups were 91.4% (95% CI, 87.0%-94.4%) and 88.1% (95% CI, 83.2%-91.6%), respectively, while the 10-year rates were 83.6% (95% CI, 77.8%-88.0%) and 72.2% (95% CI, 65.3%-78.0%). The dose-escalation of radiotherapy reduced the risk for disease progression by 44% (HR, 0.56; 95% CI, 0.40-0.76; P = .0005).

When evaluating cancer-specific survival in the dose escalation and control groups, the 5-year (98.7% [95% CI, 96.2%-99.6] vs 96.6% [95% CI, 93.3%-98.3%], respectively) and 10-year (95.6% [95% CI, 91.7%-97.7%] vs 90.0% [95% CI, 84.1%-93.8%]) rates continued to demonstrate superiority with the 80-Gy dose (HR, 0.48; 95% CI, 0.27-0.83; P = .0009).

Lastly, the dose-escalation arm showed a 5-year OS rate of 93.4% (95% CI, 89.5%-95.9%), compared with 88.7% (95% CI, 84.0%-92.0%) with the control arm, as well as 10-year OS rates of 77.0% (95% CI, 70.2%-82.4%) and 65.9% (95% CI, 58.7%-72.1%), respectively, reducing the risk for death by 39% (HR, 0.61; 95% CI, 0.44-0.85; P = .0039).

Hennequin noted that there was no difference between arms regarding toxicity and quality of life. Grade 3 or higher late genitourinary toxicities occurred in 20.6% of the high-dose arm, vs 19.9% in the control arm, while 1.6% of patients in each arm experienced a grade 3 or higher late digestive toxicity.

Hennequin noted that a variety of randomized trials have been conducted to evaluate the role of de-escalation in prostate cancer. “Most of them demonstrated an improvement in biochemical control, but no demonstrated benefit in overall survival. However, most of these trials included a low number of high-risk patients, and most of [the patients] did not choose long-term ADT. They used no ADT or short-term ADT,” he added, also acknowledging that long-term ADT is the standard of care in this patient population.

“The question remains: Is it necessary to increase the dose of radiotherapy in case of long-term ADT, or is the standard dose good enough for this patients?” Hennequin said.

Therefore, in the randomized phase 3 trial, high-risk patients were randomized 1:1 to receive either dose-escalated (80 Gy) or conventional-dose (70 Gy) radiotherapy plus 3 years of ADT to determine the efficacy and safety of dose escalation in combination with long-term ADT.

To be eligible for the trial, patients had to have high-risk prostate adenocarcinoma, with 1 of 3 factors (PSA ≥ ng/ml, Gleason ≥ 8, or cT3-T4) and a performance score of 0 to 2. Key inclusion criteria included histologically-proven prostate adenocarcinoma; disease of the unfavorable group defined by T3 or T4 clinical stage, Gleason score or serum PSA level; lymphatic dissection or cN0 ≥ 15 mm on CT or MRI; absence of bone or visceral metastases; hormone treatment beginning no later than the day of radiotherapy and no earlier than 6 months before irradiation; absence of prior pelvic radiotherapy; absence of surgical treatment for prostate cancer, except transurethral resection performed at least 3 or 4 months previously; aged 18 to 80 years; ECOG performance status of 1 or less; and life expectancy of more than 5 years.

Investigators stratified patients by lymph node resection and institution.

PFS served as the trial’s primary end point, while secondary end points included cancer-specific survival, OS, and late toxicity. In the updated evaluation of the trial, 6-year biochemical or clinical PFS was the primary end point; OS, specific survival, acute and delayed toxicities, and quality of life were the secondary end points; and exploratory end points included clinical relapse-free survival and metastasis-free survival.

In total, 505 patients from across 25 French centers were recruited from June 4, 2009, to January 24, 2013. Patients were a median age of 71 years (range, 52-80), with the majority reporting with just 1 high-risk disease factor (64.6%). Further, 16.4% of patients received lymph node dissection.

Median duration for ADT was 33.4 months, while 82.9% of patients underwent pelvic lymph node radiation, and 6 patients did not have radiotherapy performed. Interestingly, according to Hennequin, 80.6% of the dose-escalation arm received intensity-modulated radiation therapy (IMRT) in addition to ADT (P < .001).

“Obviously IMRT is required to obtain these results. So, we have now level 1 evidence that high-dose [radiotherapy] with long-term ADT must be the standard of care in high-risk prostate cancer patients,” Hennequin concluded.

Reference

Hennequin C, Sargos P, Roca L, et al. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial. J Clin Oncol. 2024;42(suppl 4). Abstract LBA259.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Fred Saad, CQ, MD, FRCS, FCAHS
Alicia Morgans, MD, MPH
Jacob E. Berchuck, MD
Alicia Morgans, MD, MPH
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital